In a strategic move to strengthen pharmaceutical security and advance national biotechnology capabilities, Amr Kandil, Deputy Minister of Health and Population, chaired the inaugural meeting of the Egyptian Vaccine Manufacturers Alliance (EVMA) Committee.
The session brought together senior officials from the Unified Procurement Authority (UPA), the Egyptian Drug Authority (EDA), and representatives from the Ministries of Finance, Planning, and Investment, alongside leading national and international vaccine manufacturers.
The meeting was convened under Ministerial Decree No. 449 of 2025, which established the committee to coordinate efforts between government agencies and the private sector, aiming to localise vaccine production and bolster preparedness for future health challenges.
Kandil reviewed two proposals from international companies focused on localising seasonal influenza vaccine manufacturing, emphasising alignment with Egypt’s strategic vision to select optimal solutions that enhance domestic production and export potential.
Hisham Badr, Vice President of the Unified Procurement Authority, highlighted Egypt’s advanced manufacturing infrastructure, noting its capacity to lead vaccine production at a continental level.
Tamer El-Husseini, EDA Vice President, affirmed full institutional support to facilitate manufacturing and export processes.
The committee outlined mechanisms for technology transfer and set implementation steps with clear timelines, fully compliant with international standards.
Discussions concluded with the adoption of a roadmap prioritising the next phase of action.
Participants affirmed that this initiative marks a critical milestone in positioning Egypt as a regional hub for vaccine production and export, strengthening health security across the Middle East and Africa and enhancing preparedness for future pandemics.
